⌘K
OverviewStock screenerAnalyst actionsTicker roomsCalendar
MarketsInvestorsSign in
StockFranceNasdaqGS

NBTX

Nanobiotix S.A.

Healthcare · Biotechnology

29.36USD

+0.1700 (+0.58%)

Alert
DescriptionHistoricalFinancialsRelative ValueResearchNewsCommunityRoomOptionsPrice Chart ↗Fundamental Chart ↗

Community sentiment

Not enough data yet

A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.

Sign in to share your take on NBTX.

Members' own stated views, weighted by account age and track record on this site (simulated portfolios and calls). Not a forecast or a price signal. How this is worked out
  • Only members whose accounts are at least 14 days old and who have a track record on this site (simulated portfolios and calls) count, and bots never do. A take from anyone else is saved and starts to count the day they qualify.
  • A take fades: it counts half as much after 7 days and drops out after 30.
  • Members with a strong record count more. Everyone else counts together for a capped share, so many accounts cannot outweigh a few strong ones.
  • Nothing is shown until 5 qualifying members have taken part, 2 of them with a strong record. It stays an early read until 3 have one and the sample is large enough.
  • Until 20 members have taken part the marker only says bullish, bearish or mixed, at a fixed spot, and the number of members is given as a band, not a count.
  • The reading is refreshed about every 30 minutes, so a take you have just made will not move it straight away.
  • Your own take is private: only the totals are shown, and never who said what.

Estimates and surprises

Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.

PeriodConsensus EPS90 days agoRevisions up (30d)Revisions down (30d)
Current year-€0.54▼€0.0410
Next year-€0.15▼€0.0711

Wall Street coverage

8 ratings from 4 firms

Ratings are attributed to the research firm, not to individual analysts. See every ticker.

FirmActionRatingPrice TargetDate
Leerink PartnersMaintainedOutperform$37 $46Jun 4, 2026
UBSMaintainedNeutral$3.5 $30May 1, 2026
GuggenheimMaintainedBuy$26 $36Apr 2, 2026
GuggenheimMaintainedBuy$8 $26Feb 6, 2026
GuggenheimMaintainedBuy$12 $8Apr 4, 2025
GuggenheimInitiatedBuy$12Aug 28, 2024
Leerink PartnersInitiatedOutperform$11Dec 8, 2023
Evercore ISI GroupInitiatedOutperform—Jan 6, 2021

Analyst Notes

Sign in to write

No analyst notes on NBTX yet.

Analyst Ratings

3 analysts covering

PeriodStrong BuyBuyHoldSellStrong SellConsensus
Current04100Buy2.20
1 mo ago04100Buy2.20
Price target$53.93$29.54 – $69.09
+83.7% to target

Top voices on NBTX

Members whose judged calls on NBTX have played out most reliably.

No settled calls on NBTX yet. Nobody has filed a call with a deadline on it.

A member is listed once they have three judged calls on a name.

Sign in to make a call

A call with a target is judged on whether the price reaches it by the deadline, counting each day's high (a buy) or low (a sell) from the day after the call was made. A call without one is judged on whether the price at the close on the deadline is higher (a buy) or lower (a sell) than the price the call was made at: the live price when it was saved, for a call made with Make a call, or the last close before the day it was filed, for a call made in a note. Not against the market or an index.

A percentage appears once five calls have reached their deadline. A target reached sooner is shown as played out early, and counts toward the percentage when its deadline passes, because a miss cannot be known before then.

A member’s prediction, judged on price history · not investment advice